During 2001–March 2020, crude prevalence of diabetes increased from 9.0% to 14.1% in the U.S. adult population. Among adults with CKD, the crude and age-adjusted prevalence was on average threefold higher than among adults without CKD. During 2017–March 2020, the crude prevalence of diabetes was 37.4% among adults with CKD vs. 10.3% among adults without CKD. Among adults with CKD, diabetes prevalence (crude) was highest among those aged 60–69 years and males. The lowest prevalence of diabetes was seen among non-Hispanic White adults with CKD.
To view the burden of Diabetes by risk categories, select from the drop-down menu below. Risk categories include CKD, Age Category, Sex, and Race/Ethnicity.
Data includes CKD stages 1–5. Estimates were standardized to the 2010 U.S. Census adult population.
Estimate for Age Category "18-39 years" was suppressed due to a large standard error stemming from a small sample size.
NHANES is a nationally representative, cross-sectional survey that is currently conducted every two years (since 1999) by CDC's National Center for Health Statistics among noninstitutionalized US civilian residents. The survey consists of a standardized in-home interview and a physical examination with blood and urine collected at a mobile examination center. Data were examined by combining two NHANES cycles to represent four-year periods from 2001 to 2016 and the 2017–March 2020 pre-pandemic cycle.
Note: Not all NHANES variables are collected for all years; therefore, some NHANES indicators may not utilize the full 20-year span.
Overall: Prevalence of diabetes among U.S. adults.
By strata: Prevalence of diabetes among U.S. adults with CKD.
National Health and Nutrition Examination Survey (NHANES).
Noninstitutionalized U.S. adults aged ≥ 18 years. Pregnant women excluded.
2001–March 2020.
Overall: U.S. adults aged ≥ 18 years with diabetes.
By strata: U.S. adults aged ≥ 18 years with CKD and diabetes.
Overall: U.S. adults aged ≥ 18 years with data for CKD and diabetes.
By strata: U.S. adults aged ≥ 18 years with CKD (eGFR < 60 ml/min/1.73 m2 or albuminuria) and data for diabetes.
CKD is defined by an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² or albuminuria (urine albumin to creatinine ratio [UACR] ≥ 30 mg/g). Estimates are based on single estimates of eGFR and UACR.
Based on the CKD-EPI (2021) equation for calibrated creatinine: eGFR=142 x [min(serum creatinine in mg/dL) /κ, 1)]^α x [max(serum creatinine/κ, 1)]^-1.20 x 0.9938^age x (1.012 if female). κ = 0.7 if female and 0.9 if male α = -0.241 if female and -0.302 if male
UACR was calculated as urine albumin divided by urine creatinine. Albuminuria is defined as UACR ≥ 30 mg/g. Urine albumin is measured in random urine collection by fluorescent immunoassay.
Serum creatinine values used for eGFR calculation were standardized against isotope dilution mass spectrometry (IDMS).
Self-reported diabetes or HbA1c ≥ 6.5%.
Estimates were standardized to the 2010 U.S. Census population for adults: 18–39 years: 37.1%, 40–59 years: 38.1%, 60–69 years: 12.8%, and 70+ years: 12.0%.
Albuminuria and kidney function were assessed from one-time cross-sectional measurements, possibly overestimating CKD prevalence.
Appropriate NHANES survey weights were used for all analyses; if relative standard error is greater than 30%, the estimates are not shown. Serum creatinine measurements are assay corrected for NHANES years 2005 and 2006 and prior to be combined with later years.
